A new change is taking place in the pharmaceutical equipment industry!

Since 2020, a new change is taking place in the pharmaceutical equipment industry: the originally popular imported pharmaceutical equipment has fallen into the dilemma of delayed delivery, and pharmaceutical companies have to turn their goals to domestic powerful local pharmaceutical companies
.
In addition, due to the limited processing and production of some overseas factories, orders are gradually shifting to Chinese production, bringing more development opportunities to domestic pharmaceutical machinery companies
.
Data show that the current scale of China's pharmaceutical equipment market is about 100 billion yuan, and it is expected to reach 200 billion yuan by 2025
.
In this context, what domestic pharmaceutical companies must do is to continuously increase R&D investment to improve their own capabilities, appropriately expand production capacity, seize the current opportunities, and strive to accept more domestic and foreign orders
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) Among them, R&D is the soul of the manufacturing industry and the core competitiveness of an enterprise
.
From the perspective of the domestic pharmaceutical machinery market, the competition among local pharmaceutical machinery companies is fierce, the homogeneity of low-end products is serious, and the number of giant companies is scarce.
Only by strengthening innovation and research and development can companies stand out
.
In the high-end field, imported equipment still occupies a monopoly, and domestic companies need to build their own core technologies through continuous research and development to gradually catch up with imported manufacturers
.
From the perspective of the needs of pharmaceutical companies, China is accelerating the implementation of a healthy China strategy.
The pharmaceutical industry is facing higher and higher quality requirements.
Only by increasing R&D investment and keeping pace with the times can pharmaceutical equipment meet the new requirements of pharmaceutical companies.
There is a risk of elimination
.
This year, many pharmaceutical machinery companies have achieved some gratifying new results by continuously increasing R&D investment
.
For example, in the case of a delay in the delivery date of imported equipment, a pharmaceutical machine company in Ningbo has seized the opportunities in the domestic market and continued to invest in new product research and development.
At present, the new prototype has entered the normal testing stage
.
It is reported that according to general equipment, the consumption of one ton of water vapor is 230 kg and 250 kg, and the new equipment breaks through the technical problems of heat energy utilization on the original basis, and effectively saves energy consumption while ensuring production quality.
The water vapor consumption per ton is only 120 kg to 130 kg, which is a half of the original energy consumption
.
The company said that the current intention order for new equipment has exceeded 20 units
.
For another example, the domestic pharmaceutical equipment giant Chutian Technology mentioned in the 2021 mid-year report that in the first half of the year, it continued to strengthen the company’s technological innovation and manufacturing capabilities.
Strategic and key customer orders were gratifying, breaking the monopoly of domestic high-end pharmaceutical equipment by foreign companies.
, And gradually opened up the situation of import substitution in the high-end equipment market
.
In the first half of 2021, the company's new orders increased by 136% over the same period of the previous year.
The relevant person in charge of Chutian Technology revealed that the company's orders are currently scheduled to 2022
.
The company also plans to continue to increase investment in research and development and advanced manufacturing technology, and strive to achieve a sales target of 20 billion yuan by 2030
.
In addition, it can be found from the express reports for the first three quarters of 2021 issued by some domestic pharmaceutical equipment companies that many companies have maintained a good momentum of development and have continued to make efforts in R&D investment
.
For example, in the first three quarters of this year, Tofflon’s R&D expenses reached 166 million yuan, which has exceeded the full-year R&D expenses of 156 million yuan in 2020, an increase of 74.
81% over the same period last year
.
With continuous high R&D investment, the R&D strength of these pharmaceutical machine companies will continue to improve, and new products will become more abundant
.
Production capacity is currently a major challenge facing domestic pharmaceutical machinery companies
.
Under the circumstances of accepting more new orders and new opportunities, the production capacity problem of pharmaceutical machinery companies has become more prominent, and it is necessary to continue to promote production capacity construction to meet the rapid supply demand of the market
.
For example, Chutian has successively established holding companies Chutian Siyoute and Chutian Microsphere this year to accelerate its deployment in the field of biopharmaceuticals; Tofflon is actively deploying disposable consumables, and the company’s plant in Zhengzhou has The plant was officially put into production in October this year.
The plant has more than 6,500 square meters of workshops.
After it is put into use, it will increase its production capacity by 500,000 sets/year, and realize the supply of Zhengzhou and Shanghai, which will greatly improve supply efficiency and shorten the delivery cycle
.